21st Pharmacovigilance 2020

21st Pharmacovigilance 2020

“Latest developments in pharmacovigilance, drug safety and RMP”

26th & 27th February 2020, Pestana Chelsea Bridge Hotel, London, UK

Who Should Attend:

CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, RMPs, PSURs, PADERs, PBRERs, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs & Compliance, Information Technology, Sales and Marketing

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Description:
21st Pharmacovigilance 2020 event keeps an immersed eye on discussion of critical topics in PV domain, which capture influence of emerging technologies like AI, IoT, Big Data. Not merely that, we have exciting surprise activities which will help you to interact more with your peers. This will be surely an exciting event wherein you could get chance to meet big industry gems. Let’s gather to shape the industry with your magnificent ideas.

Sponsors:
• Covance
• Brookwood Global

We also have more sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit/Booth/Stall and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts.

Delegate Registration:?

In order to register please contact us on Email: kavitha@virtueinsight.co.in 

Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.

Early Bird Pricing:
1 Delegate @ £999 + VAT (Valid Till 17th January 2020)
3 Delegates @ £1998 + VAT (Valid Till 17th January 2020)

Standard Pricing:
1 Delegate @ £1299 + VAT (From 18th January 2020)
3 Delegates @ £2598 + VAT (From 18th January 2020)

Key Speakers:?
• Nicholas Call, Special Agent, FDA
• Shaantanu Donde, Senior Director, Medical Portfolio Development (Developed Markets), Upjohn, Division of Pfizer
• Susan Welsh, Chief Safety Officer, CSL Behring
• Jackie Roberts, Executive Director Regulatory, Pharmacovigilance and Medical / QPPV, Accord-UK
• Scott Chandler, Vice President & Global Head Licensing and Early Development (LEAD) Safety, Roche
• John Solomon, Head of Pharmacovigilance - Uk & Ireland, Sanofi
• Michael Bean, Senior Director, BioResearch Regulatory Compliance R&D, Johnson & Johnson
• Tanja Peters, Global Head of Pv Intelligence, Deputy Eu QPPV, Boehringer Ingelheim
• Jabeen Ahmad , Global Pv Consultant, Independent Consultancy
• Wivina De Waele, Director, Regional Safety Excellence EMEA.Global Drug Safety, Alexion
Steinar Madsen , Medical Director, Norwegian Medicines Agency
• Raj Bhogal, Head of Inspection, R&d Quality, Takeda
• Philip Oluwole, Associate Principal Surveillance Specialist, Astrazeneca
• Mate a. Balazs ,country Head - Patient Safety – Hungary, Novartis
• Mircea Ciuca, Global Therapeutic Area Head - Global Clinical Safety and Pharmacovigilance, CSL Behring
• Sumit Munjal, Senior Medical Director, Head Europe Pv, Takeda Pharmaceuticals
• John Poustie, Medical Director & Eu QPPV, Global Pharmacovigilance, Norgine
• Valentina Mancini, Director Pv, Eu QPPV, Shionogi Europe
• Yuung Yuung Yap, Senior International Regulatory Counsel, Eu and International Regulatory Law, Pfizer
• Luiz Lima, Senior Global Patient Safety Physician - Neurology, Ipsen
• Franck Schwartz, Qa Global Inspection, Intelligence Lead - Compliance and Regulatory Affairs Quality, Novartis
• Karen (Heil) Cheng, Safety Risk Lead, Pfizer
• Iva Slavcevova, Deputy Qp Pharmacovigilance/global Patient Safety, Baxter
• Andrea Oliva, Head of Pharmacovigilance, Mylan
• Natalie Springveld, Global Safety Leader, Bayer
• Tea Babic, Associate Director, Audits and Inspections, Global Pharmacovigilance Compliance, Teva
• Kare Kemp, Team Leader (Senior Advisor), Signals and Risk Management - Pv/safety, Danish Medicines Agency
• Alina Tudor, Associate Director, Senior Pv Physician/ Deputy Eu QPPV, Norgine
• Yvonne Nanciu, Senior Manager Pv & Medical Information, Local QPPV, Abbvie
• Marjan Dzeparoski, Head of Regulatory Affairs, Drug Safety & Intelectual Property, Bionika Pharmaceuticals
• Chetan Shatapathy, Principal Pharamcovigilance Physician - Oncology R&d Unit, Astrazeneca
• Barbara De Bernardi, Deputy Eu QPPVand European Safety Office Head, Pfizer
• Salvatore Giorgio Cicirello, Senior Director Safety Science & Pass, Global Drug Safety & Risk Management, Celgene
• Nicole Baker, Co-founder, Biologit
• Maddalena Lino, Terapheutic Area Safety Head, Seqirus
• Mary Lynne Van Poelgeest, President, World Federation for Incontinent Patients - (Wfip)
• Sandy Eisen, Chief Medical Officer, Frontline Pharma Consulting
• Georgia Gavriilidou, Counsel, Life Sciences, Sidley Austin

Key Themes:
• Market analysis – Pharmacovigilance in 2020 - future horizons and efficiencies
• Brexit Implications for the Pharmaceutical (pharmacovigilance) Industry
• Outsourcing in Pharmacovigilance- Best Practices, Challenges and key considerations
• New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT)
• PV Audits & Inspections – Knowing what is required to be done
• Documentation (RMPs, PSURs, PADERs, PBRERs)
• Quality, Safety and Signal Detection - Future of 2020
• Medical devices – Increasing safety perspective
• Case studies from various countries on the PV frameworks around the world
• Patient centric approach to help improve patient safety
• The developing regulatory framework in advanced and developing markets – EU, USA & ROW
• Networking opportunities